Ablation Devices Market Analysis & Forecast: 2026-2033
The Global Ablation Devices Market was valued at USD 11.56 Bn in 2026 and is expected to reach USD 26.44 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.6% from 2026 to 2033. Ablation devices are gaining adoption as hospitals shift toward minimally invasive, image-guided treatment for arrhythmias, cancer, pain and gynecological disorders. Demand is supported by the global atrial fibrillation burden, estimated at 37.6 million people, and U.S. projections that 12.1 million people will have AFib by 2050. In 2026, innovation momentum strengthened as FDA PMA records showed decisions for Boston Scientific’s FARAPULSE/FARAPOINT platform and Medtronic’s PulseSelect PFA system, underscoring movement toward pulsed-field ablation. Improved precision, shorter recovery, lower thermal-injury risk and rising electrophysiology procedure volumes are expected to keep hospitals, ambulatory centers and specialty cardiac clinics at the center of adoption.
(Source: CDC)
The Global Ablation Devices Market is growing due to rising cardiovascular diseases, technological advancements, and an aging population. Ablation devices remove abnormal tissue minimally invasively, avoiding surgery. Radiofrequency ablation (RFA) uses high-frequency waves to heat and destroy tumors in organs like the liver and lungs, offering quick recovery. Microwave ablation (MWA) uses microwaves to more effectively treat larger tumors. For instance, in 2023, microwave ablation was successfully used to shrink a large liver tumor, demonstrating its effectiveness and patient benefits.
The increasing incidence of cancer cases around the world is a major factor fueling the expansion of the global ablation devices market. Cancer has become one of the leading causes of death worldwide, with nearly 10 million deaths in 2020, according to the World Health Organization. The growing burden of various types of cancer such as liver cancer, lung cancer, kidney cancer, and others, is driving greater demand for effective ablation techniques that can help in cancer treatment.
Ablation techniques have emerged as viable, minimally invasive alternatives to surgery in recent years for cancer treatment. Ablation devices help destroy cancerous tumors or unnecessary tissues by imparting heat or cold. Various devices in this market, such as radiofrequency ablation devices, microwave ablation devices, cryoablation devices, hydrothermal ablation devices, and others, are being widely adopted.
This is due to advantages such as shorter hospital stays, reduced recovery time, and less pain for patients compared to conventional surgery. The rising preference for minimally invasive procedures will aid in the increasing incorporation of ablation techniques in clinical oncology.
Ablation treatment is increasingly being used for age-related chronic diseases and conditions like atrial fibrillation, cancer, and cardiovascular diseases, which are highly prevalent in older age groups. For example, according to the World Health Organization (WHO), atrial fibrillation, a type of irregular heartbeat that can lead to strokes, heart failure, and other complications, affects around 6 million people in the European Region alone, and its incidence rises with age from less than 1% at age 50 to almost 10% at age 80. Similarly, the American Cancer Society (ACS) estimates that around 66% of all cancers are diagnosed in people aged 65 years or older.
Ablation offers minimally invasive techniques to treat such diseases with fewer side effects than alternative options like open surgeries for the aging population. As people across the world opt for radiofrequency, cryoablation, microwave, and other catheter-based techniques over surgical treatments, the demand and scope for the application of ablation systems for chronic disease management in older age segments are surging rapidly. This steady rise in diseases and conditions afflicting the ballooning senior citizen demographic globally will remain a key driver propelling the multibillion ablation devices industry forward in the forthcoming years.
The global market for ablation devices is receiving a boost due to new and emerging technologies for ablation devices. Ablation is a minimally invasive procedure that employs technologies such as radiofrequency, laser and light, ultrasound, and others to destroy the tissues that are damaged.
The latest generations of ablation devices tend to enable physicians to manage complex medical problems more accurately and more effectively. For example, some modern laser systems make it possible to ablate tumors in the lungs- even in inaccessible locations, which aids considerably in making surgical cuts.
These improvements make the risks and recovery times faster and better for patients. One additional aspect of importance as to why the global market for ablation devices is expanding is the development of Magnetic Resonance Guided Focused Ultrasound (MRgFUS ) technology by prominent players within the industry. MRgFUS incorporates MRI imaging and focused ultrasound beams to non-invasively ablating tissues like fibroids at the uterus. MRgFUS is gaining acceptance for essential tremors and bone metastases.
Unlike conventional surgical procedures, MRgFUS Does not introduce any form of malignancy. According to the U.S. National Institute of Biomedical Imaging and Bioengineering (2020), more than 20,000 patients had received treatment with gynecological MR-guided focused ultrasound systems worldwide by 2020.
The emerging economies in Asia Pacific and Latin America regions are well positioned to drive significant growth in the global ablation devices market in the coming years. Countries like India, China, Brazil, and Mexico have very large patient populations combined with improving access to healthcare facilities. As disposable incomes and standards of living rise rapidly in these developing nations, access to advanced medical technologies and procedures will also increase dramatically.
Ablation devices are increasingly used in minimally invasive treatments for cancer, cardiac arrhythmias, and other conditions. As the burden of non-communicable diseases grows in the developing world due to lifestyle changes and aging populations, demand for ablation technologies from physicians and patients will continue to surge. These emerging markets still have much lower device utilization and procedure rates compared to developed countries currently. This indicates a massive potential for future procedure volume growth as affordability barriers reduce over time.
Growing applications of ablation devices in a variety of medical procedures have created significant opportunity in the global ablation devices market. Ablation procedures are increasingly being used as minimally invasive alternatives for surgeries across various therapeutic areas like cardiology, gynecology, urology, and many others.
According to data published in June 2024, the Center for Disease Control and Prevention, cancer incidence and mortality rates have declined annually from 2016 to 2019 in the U.S., partly due to early detection and advanced interventional procedures like ablation that help treat cancer without the need for major invasive surgeries.
This ablation devices are becoming the standard of care for treating arrhythmias and replacing the need for lifelong medication. According to the World Health Organization, cardiovascular diseases are the leading cause of mortality worldwide, responsible for over 17 million premature deaths annually. Ablation offers effective treatment with high success and lower risks than alternative drug therapies or extensive surgical procedures for heart conditions. Industry projections suggest more than half a million cardiac ablation procedures are performed worldwide each year, and this figure is expected to grow substantially in the coming years.
|
Event |
Description and Impact |
|
Technological Advancement and Innovation Wave |
|
|
Regulatory Landscape Evolution |
|
|
Global Healthcare Infrastructure Transformation |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The Ablation Devices Market faces a global reimbursement system which is intertwined with device adoption and patient access. The blank reimbursement is attributed to ablative procedures CPT codes which contain of pathologic modalities, for example CPT 93656 for atrial fibrillation and CPT 47370 for liver tumor ablation. It is also facilitated by supporting diagnosis codes from ICD-10 and device specific hcpcs codes.
In the US, reimbursement policies set by CMS NCDs and LCDs, are likely to cover these ablation procedures within Medicare Parts A and B. Medicare covers catheter ablation procedures at an estimated price of 15,000 to 25,000 dollars and pays approximately 80 percent of the approved costs post deductible, while the patient coinsurance is 20 percent on average. Medicaid coverage differs from state to state but does provide coverage for most ablation procedures.
In Europe, MCDA decisions are made by the national HTA bodies such as NICE UK and G-BA Germany, working within EMA regulatory frameworks. In the Asia pacific region, Japan’s MHLW and China’s NMPA supervise a fragmented reimbursement ecosystem, which is becoming more supportive as ablation therapies are increasingly used. As discussed, the objectives regarding other regions highlight the importance that these policies have on commercial and widespread use of ablation devices, irrespective of oncology and cardiac arrhythmia indications.
The radiofrequency ablation segment leads the ablation devices market with a significant 36.5% revenue share in 2026. This dominance is driven by its widespread use in treating cancerous tumors and cardiovascular diseases due to its minimally invasive nature and faster patient recovery. From 2025 to 2050, cardiovascular prevalence is expected to rise by 90.0%. Technological advancements and growing clinical adoption further support the segment’s leadership.
Microwave ablation holds a notable share as well, favored for its effectiveness in treating larger tumors. Other technologies, including cryoablation, ultrasound ablation, and hydrothermal ablation, contribute to the market but have comparatively smaller shares. Continuous innovation and expanding treatment applications are expected to fuel growth across these segments.
To learn more about this report, Request Free Sample
Hospitals account for the largest share of 66.4% in 2026 in the global ablation devices market due to high procedural complexity, availability of electrophysiology (EP) laboratories, and the need for multidisciplinary clinical infrastructure to manage cardiac, oncology, and pain-related ablation procedures. According to the American Heart Association (AHA) Scientific Statement (March 2024), catheter ablation especially for atrial fibrillation is primarily performed in hospital EP labs because continuous cardiac monitoring, imaging guidance, and emergency intervention capabilities are essential. The CDC Heart Disease & Stroke Statistics update (February 2026) reports rising atrial fibrillation prevalence in the U.S., driving higher hospital-based intervention volumes and inpatient electrophysiology procedures. Additionally, FDA PMA approvals (2026) for advanced RF and pulsed-field ablation systems such as FARAPULSE and PulseSelect indicate that most devices are cleared for hospital use, reinforcing institutional dominance. Furthermore, WHO cardiovascular disease fact sheets (2024 update) highlight that CVD-related procedures remain concentrated in tertiary hospitals globally due to infrastructure and specialist availability.
To learn more about this report, Request Free Sample
North America leads the global ablation devices market, holding a dominant 42.0% share in 2026. This leadership stems from the growing preference among physicians for laser ablation techniques to treat conditions such as atrial fibrillation and cancerous tumors. Laser ablation offers enhanced precision and control over tissue removal compared to other technologies, driving its widespread adoption. The region benefits from advanced healthcare infrastructure, strong clinical expertise, and high healthcare expenditure, supporting continued market growth. U.S. healthcare spending increased by 7.3% in 2025, reaching $5.7 trillion, driven primarily by higher hospital expenditures and increased spending on GLP-1 medications.
Europe is the second-largest market for ablation devices, capturing a 29% share in 2026. The market expansion is primarily driven by the extensive adoption of radiofrequency ablation therapy for cardiac arrhythmias. Favorable reimbursement frameworks, increasing awareness among healthcare providers, and ongoing technological innovations in ablation therapy contribute to the steady growth of the market across European countries.
Asia Pacific holds the third-largest share at 18% in 2026, with rapid growth fueled by the rising use of ultrasound ablation technology. This technology’s safety and precision advantages make it a preferred choice for treating certain medical conditions. Improving healthcare infrastructure, increased investment in medical technologies, and growing awareness of minimally invasive treatment options are key factors driving market adoption in the region.
The U.S. dominates the North American market, driven by widespread use of laser ablation procedures and strong healthcare R&D investments. High adoption rates are supported by a large patient pool with cardiac and oncological conditions and well-established reimbursement policies.
Germany leads the European ablation devices market, supported by its advanced healthcare system and extensive use of radiofrequency ablation therapy. The country’s focus on clinical research and technology adoption ensures sustained growth in this segment.
China is a key market in Asia Pacific, with growing adoption of ultrasound ablation driven by expanding healthcare infrastructure and increased access to advanced medical technologies. Government initiatives promoting healthcare modernization and rising patient awareness contribute to the rapid market expansion. India launched Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY), the world's largest government-funded health assurance scheme, providing free hospital coverage of up to INR 5 lakh (USD 5,600.89) per family. As of June 2025, the scheme covers approximately 12.37 crore economically vulnerable families, benefiting around 55 crore individuals.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 11.56 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.6% | 2033 Value Projection: | USD 26.44 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic, Johnson & Johnson Services, Inc., Abbott, Smith+Nephew., Boston Scientific Corporation, AngioDynamics, ATRICURE, INC., Olympus Corporation, CONMED Corporation, Merit Medical Systems |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
(Source: Francis Medical)
Definition: Ablation devices are designed to ablate (remove or destroy) tissue for therapeutic purposes and often used in the treatment of various types of diseases and medical conditions, including cardiac arrhythmias, cancer tumors, and other dysfunctional tissues. These devices function by delivering energy to the targeted tissues and can employ various techniques based on the type of energy they utilize, such as radiofrequency ablation, cryoablation, laser ablation, microwave ablation, electrical ablation, ultrasound ablation, etc.
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
